Earlier studies have shown that butyrate can inhibit the progression of non-alcoholic fatty liver disease (NAFLD) by activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, thereby regulating lipid and energy metabolism, insulin sensitivity, and oxidative stress [52]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.